| Autor: |
Fairchild L; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., Whalen J; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., D'Aco K; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., Wu J; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., Gustafson CB; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., Solovieff N; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., Su F; Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA., Leary RJ; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., Campbell CD; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA., Balbin OA; Novartis Institutes for BioMedical Research Inc., Cambridge, MA 02139, USA. |
| Abstrakt: |
In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA sequencing alone, applying our model to 4324 oncology clinical cfDNA samples. Using this method, we determined that 30.3% of patients in this cohort have evidence of CH, and the incidence of CH varies by tumor type. Matched RNA sequencing data show evidence of increased inflammation, especially neutrophil activation, within the tumors and tumor microenvironments of patients with CH. In addition, patients with CH had evidence of neutrophil activation systemically, pointing to a potential mechanism of action for the worse outcomes associated with CH status. Neutrophil activation may be one of many mechanisms, however, because patients with estrogen receptor-positive breast cancer harboring TET2 frameshift mutations had worse outcomes but similar neutrophil frequencies to patients without CH. Together, these data show the feasibility of detecting CH through cfDNA sequencing alone and an application of this method, demonstrating increased inflammation in patients with CH both systemically and in the tumor microenvironment. |
